Affiliations: [a] Department of Biomedical Technology, National Research Center, Cairo, Egypt | [b] Department of Biochemistry, Faulty of Science, Ain Shams University, Cairo, Egypt | [c] Department of applied Biology, Nuclear Research Center, Atomic Energy Authority, Cairo, Egypt | [d] Gastroenterology Department Police Hospital, Cairo, Egypt | [e] Department of Research on Children with Special Needs, National Research Center, Cairo, Egypt
Correspondence:
[*]
Corresponding author: Prof Mostafa K. El Awady, Chair man of Biomedical Technology Section, National Research Center, Cairo, Egypt. Tel.: +201 231 32640; E-mail: mkawady@yahoo.com.
Abstract: The study was planned as a pilot study to investigate two common polymorphisms in the MTHFR gene c.677C > T and c.1298A > C and their association with enhanced risk of colorectal cancer (CRC) in a sample of Egyptian individuals. Venous blood samples were withdrawn from 35 cases of CRC and 68 healthy controls. Specimens from colonic and rectal carcinoma tissues in addition to cancer free tissues were obtained from all cases. Frequencies of MTHFR677T and 1298C alleles were significantly higher among cases of CRC tumor tissues (50% and 56%, respectively) than germ line alleles in CRC patients (33% and 41%, respectively) and healthy controls (21% and 35%, respectively). Frequencies of heterozygous and homoyzgous polymorphisms of MTHFR at positions 677 and 1298 in carcinoma tissues were always the highest. At position 677, TT and CT genotype frequencies were 17% and 66% with an odds ratio {OR} of 11 [95% confidence interval {CI} 2.39–50.59] and OR 8.34 [95%CI 2.97–23.92], respectively, in carcinoma tissues. While in the germ line of patients the genotype frequencies of 677TT and CT were 6% and 54% with OR 1.57 [95%CI 0.26–9.51] and 2.99 [95%CI 1.25–7.12], respectively, compared to controls (6% and 29%, respectively). The combined genotype MTHFR 1298CC + AC frequencies were 86% with OR 3.71 [95%CI 1.28–10.78] in carcinoma tissues, 69% with OR 1.35 [95%CI 0.57–3.21] in germ line of patients and 62% in controls. The combined genotype 677CT plus any of the following genotypes 1298AA, AC or CC enhanced risk of CRC, when comparing germ line DNA polymorphism of patients versus peripheral blood DNA of control subjects with OR 4.5 [95%CI 0.94–21.56], OR 3.12 [95%CI 0.79–12.36] and OR 18 [95%CI 1.56–207.5], respectively, suggesting strong genetic predisposition of certain Egyptian population to CRC. These results suggested that at least one C to T polymorphism at 677MTHFR gene is required to significantly increase the risk for CRC development. Further large scale studies are required to confirm the present findings.
